TCM
NVCR icon

TD Capital Management’s NovoCure NVCR Stock Holding History

TD Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18
Closed -$233 – 895
2025
Q4 		$233 Hold
18
– – ﹤0.01% 783
2025
Q3 		$233 Hold
18
– – ﹤0.01% 675
2025
Q2 		$320 Hold
18
– – ﹤0.01% 673
2025
Q1 		$321 Buy
+18
New +$409 ﹤0.01% 626

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

TD Capital Management's NVCR Position: Q1 2026 in Review

TD Capital Management sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 18 shares — an estimated $233 sold.

TD Capital Management first reported a position in NVCR in Q1 2025 and held it in 4 quarters. The position peaked at $321 in Q1 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • TD Capital Management reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • TD Capital Management sold 18 NovoCure shares in Q1 2026, an estimated $233.
  • TD Capital Management first reported a position in NovoCure in Q1 2025 and held it in 4 quarters.
  • TD Capital Management's NovoCure position peaked at $321 in Q1 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.